S

Σ


ט

0

4



## Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis









This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means – electronic, mechanical or other – without prior written permission of WHO.

Ce document n'est pas destiné à être distribué au grand public et tous les droits y afférents sont réservés par l'Organisation Mondial de la Santé (OMS). Il ne peut être commenté, résumé, cité, reproduit ou traduit, partiellement ou en totalité, sans une autorisation préalable écrite de l'OMS. Aucune partie ne doit être chargée dans un système de recherche documentaire ou diffusée sous quelque forme ou par quelque moyen que ce soit – électronique, mécanique, ou autre – sans une autorisation préalable écrite de l'OMS.

## **ACKNOWLEDGEMENTS**

This Guideline for Programme Managers was developed following an international workshop held in Atlanta, USA in July 1999, organized and hosted by:

- The World Health Organization
- The Centers for Disease Control and Prevention (CDC), Atlanta, USA
- The CDC Foundation, Atlanta, USA

The workshop and subsequent production of the Guideline were supported by an educational grant from:

• SmithKline Beecham

with additional travel grant support from:

• The Arab Fund for Economic and Social Development.



## TABLE OF CONTENTS

1.	INTRODUCTION
	I.I Make a commitment to the goal of lymphatic filariasis elimination
	I.2 Establish the National Task Force (NTF-ELF)
	1.3 Appoint a national programme manager/coordinator
2.	SITUATION ANALYSIS
	2.1 Designate the implementation unit (IU)
	2.2 Assess the distribution of infection and disease
3.	REVIEW AVAILABLE HUMAN RESOURCES
	AND INSTITUTIONAL LINKAGES9
	3.1 Within the Ministry of Health
	<b>3.2</b> Other ministries
	<b>3.3</b> Private sector
	3.4 Identify the NGDOs which can collaborate
	<b>3.5</b> Outside the country
4.	ASSESS THE SOCIAL AND ECONOMIC IMPACT OF LYMPHATIC
	FILARIASIS, ESPECIALLY IN DEPRIVED COMMUNITIES
5.	DESIGN THE LF ELIMINATION STRATEGIES
	5.1 Plan for morbidity (disability) control
	5.2 Plan for interruption of LF transmission through mass drug administration 14-20
	5.3 Integrate vector control measures with existing malaria
	and/or vector control training control programme
6.	ESTIMATE DRUG REQUIREMENTS
	6.1 Design drug procurement and distribution strategy and quality assurance21
	<b>6.2</b> Calculating requirements and procuring drugs

## TABLE OF CONTENTS

<b>7.</b>	SURVEILLANCE FOR LYMPHATIC FILARIASIS	
	7.1 Background surveillance	
	7.2 Sentinel surveillance	0
8.	PLAN INFORMATION AND EDUCATION CAMPAIGN STRATEGIES 31-3	2
9.	DEFINE A PROGRAMME IMPLEMENTATION INFRASTRUCTURE 33-3	5
10.	TRAINING AND CAPACITY BUILDING	9
11.	PREPARE THE BUDGET FOR THE PELF41	
12.	SET NATIONAL OBJECTIVES AND TARGETS43-4	4
13.	MPLEMENTATION OF ACTIVITIES45	
14.	MONITOR AND SUPERVISE ACTIVITIES AND OUTCOMES 47-4	8
15.	PERIODIC INDEPENDENT EVALUATIONS49	
GLOSS	ARY OF TERMS51	
REFER	NCES 53	
Annex	: Interview of key informants	
Annex	a: Proforma for recording household members for mass drug administration56	
Annex	b: Proforma for recording actual coverage	
Annex	c: Proforma for district compilation of drug coverage and reporting	
Annex	d: Proforma for regional compilation of district-wise drug coverage and reporting 59	
Annex	Proforma for recording longitudinal coverage and microfilaraemia rates	
Annex	: Allocation of LF expenses	2
Annex	: Guideline for monitoring the distribution of co-administered	
	albendazole and DEC during filariasis elimination programmes	5

**PREFACE** 

This document is a guideline for managers for planning and establishing a programme for the elimination of lymphatic filariasis.

It is intended for use by national programme managers, programme officials and consultants to the ministries of health in countries where lymphatic filariasis is known, or suspected, to be endemic, but not for use in countries where onchocerciasis is co-endemic with lymphatic filariasis or where the use of diethylcarbamazine citrate (DEC) is contraindicated. National Programme managers of these countries may consult the respective guideline relevant to onchocerciasis co-endemic countries. The epidemiology and clinical manifestations of lymphatic filariasis are not described in this document as extensive information on the subject is readily available elsewhere.

Throughout this document, the term "region" and "district" are used to describe administrative divisions. Each country may have its own nomenclature to describe them. Some comparable terms are listed below:

Region	District
State	Local government area (LGA)
Province	sector

Some countries have advanced into implementation of LF programmes while others have yet to start programmes using the revised recommended strategies. This guide is written in a logical order of programme development and implementation so as to be helpful to programme managers in different situations. The guide is structured so that it may also be used as a reference manual.

The manual will be adapted and changed as the LF community "learns-by-doing", and all comments and suggestions for changes to the manual are welcome. Suggestions should be addressed to filariasis@who.int. (or, WHO, 1211 Geneva 27, Switzerland, through the relevant WHO Regional Office).



https://www.yunbaogao.cn/report/index/report?reportId=5\_30479

